$BMEA News

Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow

Reported Friday, Biomea Fusion Presents ADA Data Showing Icovamenib Delivers 1.8% Placebo-Adjusted HbA1c Reduction In T2D Patients On Background GLP-1 Therapy

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion Partners With The University Of Leicester For Ongoing Platform Research Study Titled 'Investigating And Optimizing Physical Function With Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial'

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate

Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026

Citizens Initiates Coverage On Biomea Fusion with Market Outperform Rating, Announces Price Target of $9

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib

Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript

Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes - Slideshow

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion Reveals 52-Week Results From Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment; In Patients Diagnosed Within 0-3 Years, Treatment With Icovamenib 200 Mg Once Daily For 12 Weeks Resulted In A 52% Increase In Mean C-peptide Area Under The Curve At Week 12

Biomea Fusion shares are trading higher after the company announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes.

Biomea Fusion shares are trading higher after the company announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes.